Skip to main content
  • Saved

made a Post

The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland - BioDrugs

The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland - BioDrugs

Source :

https://link.springer.com/article/10.1007/s40259-022-00540-y

Background Biological drugs are generally expensive and produce a continuously growing share of drug costs. Yet they are essential in the treatment of many chronic diseases. Biosimilars, clinically equivalent to biological originator products, are expected to restrain drug costs in the biological market.


Conclusions: Changes in pricing policy and the public reimbursement scheme related to the market entry of biosimilars were the main reasons for the decrease in the prices of reference products. Therefore, biosimilars did not generate genuine price competition between biological products. In many of the drug groups examined, the market shares of biosimilars have growth potential in the future.